PUBLISHER: Grand View Research | PRODUCT CODE: 1908201
PUBLISHER: Grand View Research | PRODUCT CODE: 1908201
The global drug delivery devices market size was valued at USD 463.8 billion in 2025 and is projected to reach USD 841.4 billion by 2033, growing at a CAGR of 7.8% from 2026 to 2033. The growing adoption of advanced technology for precise drug delivery is driving market expansion.
In June 2024, Aptar Digital Health and SHL Medical partnered to enhance injectable therapy experiences by integrating Aptar's SaMD platform with SHL's connected drug delivery solutions, including the Molly Connected Cap. This collaboration aims to improve self-injection therapy through digital health innovations. These devices optimize the connected drug delivery devices market, minimizing dosage and side effects, which lowers costs by reducing active pharmaceutical ingredient use. The novel drug delivery devices market is also anticipated to witness accelerated R&D efforts owing to rising demand.
Drug delivery devices are used for conditions such as asthma, chronic obstructive pulmonary disease (COPD), diabetes, cancer, cardiovascular diseases, and chronic pain. These devices ensure precise, targeted delivery of medications, improving efficacy and patient compliance while minimizing side effects. According to the Asthma and Allergy Foundation of America, Asthma affects over 27 million people in the U.S., roughly 1 in 12 individuals. Among adults aged 18 and older, over 22 million have asthma, with a higher prevalence in females (10.8%) compared to males (6.5%). Asthma ranks among the most common and expensive diseases in the U.S. For instance, according to National Asthma Council Australia Ltd, the Salflumix Easyhaler, added to the Pharmaceutical Benefits Scheme (PBS) on April 1, 2024, treats asthma and COPD with fluticasone propionate/salmeterol in two strengths: 250/50 and 500/50. It is a dry powder inhaler that requires shaking before use and has a dose counter. The Easyhaler is suitable for various ages and disease severities. In addition, it is entirely carbon neutral.
The rising elderly population has heightened the need for subcutaneous devices for diagnosing and treating various chronic health conditions. Studies indicate that individuals aged 65 and older face increased risks of serious ailments such as heart disease, asthma, respiratory infections, COPD, diabetes, and other disorders, as aging weakens the immune system, thus driving the subcutaneous drug delivery devices market.
Global Drug Delivery Devices Market Report Segmentation
This report forecasts revenue growth at global, regional and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global drug delivery devices market report on the basis of product, application, end use, and region: